Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
AL-8326 by Advenchen Laboratories for Non-Small Cell Lung Cancer: Likelihood of Approval
AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Non-Small Cell Lung Cancer. According to...
AL-8326 by Advenchen Laboratories for Solid Tumor: Likelihood of Approval
AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
AL-8326 by Advenchen Laboratories for Pancreatic Cancer: Likelihood of Approval
AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...
AL-8326 by Advenchen Laboratories for Head And Neck Cancer: Likelihood of Approval
AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Head And Neck Cancer. According to...
AL-8326 by Advenchen Laboratories for Liver Cancer: Likelihood of Approval
AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Liver Cancer. According to GlobalData, Phase...
AL-8326 by Advenchen Laboratories for Colon Cancer: Likelihood of Approval
AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Colon Cancer. According to GlobalData, Phase...
AL-8326 by Advenchen Laboratories for Cervical Cancer: Likelihood of Approval
AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Cervical Cancer. According to GlobalData, Phase...
AL-8326 by Advenchen Laboratories for Prostate Cancer: Likelihood of Approval
AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Prostate Cancer. According to GlobalData, Phase...
AL-8326 by Advenchen Laboratories for Ovarian Cancer: Likelihood of Approval
AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...
AL-8326 by Advenchen Laboratories for Breast Cancer: Likelihood of Approval
AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Breast Cancer. According to GlobalData, Phase...
AL-8326 by Advenchen Laboratories for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to...
Catequentinib hydrochloride by Advenchen Laboratories for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Catequentinib hydrochloride is under clinical development by Advenchen Laboratories and currently in Phase II for Head And Neck Squamous Cell...
Catequentinib hydrochloride by Advenchen Laboratories for Oropharyngeal Cancer: Likelihood of Approval
Catequentinib hydrochloride is under clinical development by Advenchen Laboratories and currently in Phase II for Oropharyngeal Cancer. According to GlobalData,...
Catequentinib hydrochloride by Advenchen Laboratories for Laryngeal Cancer: Likelihood of Approval
Catequentinib hydrochloride is under clinical development by Advenchen Laboratories and currently in Phase II for Laryngeal Cancer. According to GlobalData,...
Catequentinib hydrochloride by Advenchen Laboratories for Hypopharyngeal Cancer: Likelihood of Approval
Catequentinib hydrochloride is under clinical development by Advenchen Laboratories and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData,...
Catequentinib hydrochloride by Advenchen Laboratories for Nasopharyngeal Cancer: Likelihood of Approval
Catequentinib hydrochloride is under clinical development by Advenchen Laboratories and currently in Phase II for Nasopharyngeal Cancer. According to GlobalData,...
Catequentinib hydrochloride by Advenchen Laboratories for Metastatic Ovarian Cancer: Likelihood of Approval
Catequentinib hydrochloride is under clinical development by Advenchen Laboratories and currently in Phase III for Metastatic Ovarian Cancer. According to...
AL-8326 by Advenchen Laboratories for Bladder Cancer: Likelihood of Approval
AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Bladder Cancer. According to GlobalData, Phase...
AL-8326 by Advenchen Laboratories for Small-Cell Lung Cancer: Likelihood of Approval
AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...
AL-2846 by Advenchen Laboratories for Thyroid Cancer: Likelihood of Approval
AL-2846 is under clinical development by Advenchen Laboratories and currently in Phase II for Thyroid Cancer. According to GlobalData, Phase...